-
TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA
•
Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National Medical Products Administration (NMPA) of China has accepted a Biologic License Application (BLA) for eftansomatropin alfa (TJ101) for review. This product, the first and currently only fusion protein long-acting growth hormone, is anticipated to offer…
-
I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024
•
US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD, MBA, as its permanent Chief Executive Officer (CEO), effective November 1, 2024. Dr. Fu, who has been serving as Interim CEO since July 15, 2024, will also continue his role as a member of the…
-
I-Mab’s Plonmarlimab Receives Breakthrough Therapy Designation in China for R/R MAS Treatment
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced that its proprietary human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody, plonmarlimab, is poised to receive breakthrough therapy designation (BTD) from the National Medical Products Administration (NMPA) for the treatment of recurrent/refractory hemophagocytic lymphohistiocytosis (R/R MAS), a severe and life-threatening condition. Plonmarlimab is…
-
I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments
•
I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure. Wei Fu, currently the CEO of venture capital fund CBC Group and I-Mab’s founding shareholder, has been appointed as the chairman of the board. Fu succeeds Dr. Pamela M. Klein, who is stepping down from…
-
I-Mab CEO Outlines Streamlined US Entity’s Focus and Potential for In-Licensing
•
I-Mab (NASDAQ: IMAB), a biopharmaceutical company that recently restructured into separate US and Chinese entities, has detailed its current strategic direction and streamlined operations. US CEO Raj Kannan discussed the company’s new focus at an investor conference, as reported by Endpoints News with a transcript from AlphaSense. This marks Kannan’s…
-
I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million
•
I-Mab (NASDAQ: IMAB), a biotech company transitioning to a U.S.-based entity, has announced plans to divest all its assets in China. The company has entered into agreements with I-Mab Biopharma (Hangzhou) Co., Ltd and a consortium of Chinese investors to sell its operations in China, including its remaining equity interest…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
•
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for their CD38 monoclonal antibody (mAb), felzartamab. This designation highlights the drug’s potential as a treatment for primary membranous nephropathy (PMN), a rare…
-
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises Ltd, announcing the termination of their license and collaboration agreement concerning CD47 antibody compounds and products. The agreement, initially signed on September 3, 2020, and amended on August 15, 2022, will officially end on November…
-
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
•
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to accelerate biomarker-driven clinical studies and explore the cutting edge of companion diagnostics (CDx) development. Financial details of the partnership were not disclosed. Clinical and Development ContextWith the deepening of research on tumor pathogenesis, immunotherapy, particularly…
